{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T14:37:15Z","timestamp":1792679835334,"version":"4.5.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Aligning Science Across Parkinson\u2019s","award":["ASAP-020527"],"award-info":[{"award-number":["ASAP-020527"]}]},{"name":"Aligning Science Across Parkinson\u2019s","award":["ASAP-020527"],"award-info":[{"award-number":["ASAP-020527"]}]},{"name":"Aligning Science Across Parkinson\u2019s","award":["ASAP-020527"],"award-info":[{"award-number":["ASAP-020527"]}]},{"name":"Aligning Science Across Parkinson\u2019s","award":["ASAP-000375"],"award-info":[{"award-number":["ASAP-000375"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Growing evidence indicates that persons with Parkinson disease (PD), have a unique composition of indigenous gut microbes. Given the long prodromal or pre-diagnosed period, longitudinal studies of the human and rodent gut microbiome before symptomatic onset and for the duration of the disease are currently lacking. PD is partially characterized by the accumulation of the protein \u03b1-synuclein (\u03b1-syn) into insoluble aggregates, in both the central and enteric nervous systems. As such, several experimental rodent and non-human primate models of \u03b1-syn overexpression recapitulate some of the hallmark pathophysiologies of PD. These animal models provide an opportunity to assess how the gut microbiome changes with age under disease-relevant conditions. Here, we used a transgenic mouse strain, which overexpress wild-type human \u03b1-syn to test how the gut microbiome composition responds in this model of PD pathology during aging. Using shotgun metagenomics, we find significant, age and genotype-dependent bacterial taxa whose abundance becomes altered with age. We reveal that \u03b1-syn overexpression can drive alterations to the gut microbiome composition and suggest that it limits diversity through age. Taxa that were most affected by genotype-age interaction were\n                    <jats:italic>Lactobacillus<\/jats:italic>\n                    and\n                    <jats:italic>Bifidobacteria<\/jats:italic>\n                    . In a mouse model, we showed direct link between alpha synuclein geneotype (hallmark of PD), a dysbiotic and low-diversity gut microbiome, and dysbiotic levels of\n                    <jats:italic>Bifidobacteria<\/jats:italic>\n                    and\n                    <jats:italic>Lactobacillus<\/jats:italic>\n                    (most robust features of PD microbiome). Given emerging data on the potential contributions of the gut microbiome to PD pathologies, our data provide an experimental foundation to understand how the PD-associated microbiome may arise as a trigger or co-pathology to disease.\n                  <\/jats:p>","DOI":"10.1038\/s41598-024-82139-7","type":"journal-article","created":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T13:22:49Z","timestamp":1738416169000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Alpha synuclein overexpression can drive microbiome dysbiosis in mice"],"prefix":"10.1038","volume":"15","author":[{"given":"Timothy R.","family":"Sampson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary D","family":"Wallen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Woong-Jai","family":"Won","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David G.","family":"Standaert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haydeh","family":"Payami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley S.","family":"Harms","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,1]]},"reference":[{"issue":"5321","key":"82139_CR1","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1126\/science.276.5321.2045","volume":"276","author":"MH Polymeropoulos","year":"1997","unstructured":"Polymeropoulos, M. H. et al. Mutation in the alpha-synuclein gene identified in families with Parkinson\u2019s disease. Science 276(5321), 2045\u20132047 (1997).","journal-title":"Science"},{"issue":"6","key":"82139_CR2","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1001\/jama.296.6.661","volume":"296","author":"DM Maraganore","year":"2006","unstructured":"Maraganore, D. M. et al. Collaborative analysis of alpha-synuclein gene promoter variability and Parkinson disease. JAMA 296(6), 661\u2013670 (2006).","journal-title":"JAMA"},{"issue":"6","key":"82139_CR3","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1002\/ana.21380","volume":"63","author":"OA Ross","year":"2008","unstructured":"Ross, O. A. et al. Genomic investigation of alpha-synuclein multiplication and parkinsonism. Ann. Neurol. 63(6), 743\u2013750 (2008).","journal-title":"Ann. Neurol."},{"issue":"1","key":"82139_CR4","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1002\/mds.28264","volume":"36","author":"AS Harms","year":"2021","unstructured":"Harms, A. S. et al. Inflammation in experimental models of alpha-synucleinopathies. Mov. Disord 36(1), 37\u201349 (2021).","journal-title":"Mov. Disord"},{"issue":"Suppl 1","key":"82139_CR5","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1111\/jnc.13627","volume":"139","author":"LA Volpicelli-Daley","year":"2016","unstructured":"Volpicelli-Daley, L. A. et al. How can rAAV-alpha-synuclein and the fibril alpha-synuclein models advance our understanding of Parkinson\u2019s disease? J. Neurochem 139(Suppl 1), 131\u2013155 (2016).","journal-title":"J. Neurochem"},{"issue":"5","key":"82139_CR6","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1007\/s00702-002-0808-2","volume":"110","author":"H Braak","year":"2003","unstructured":"Braak, H. et al. Idiopathic Parkinson\u2019s disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen. J. Neural Transm (Vienna) 110(5), 517\u2013536 (2003).","journal-title":"J. Neural Transm (Vienna)"},{"issue":"6","key":"82139_CR7","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1002\/mds.25020","volume":"27","author":"KM Shannon","year":"2012","unstructured":"Shannon, K. M. et al. Is alpha-synuclein in the colon a biomarker for premotor Parkinson\u2019s disease? Evidence from 3 cases. Mov. Disord 27(6), 716\u2013719 (2012).","journal-title":"Mov. Disord"},{"issue":"4","key":"82139_CR8","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1002\/ana.24448","volume":"78","author":"E Svensson","year":"2015","unstructured":"Svensson, E. et al. Vagotomy and subsequent risk of Parkinson\u2019s disease. Ann. Neurol. 78(4), 522\u2013529 (2015).","journal-title":"Ann. Neurol."},{"issue":"3","key":"82139_CR9","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/s41593-020-0589-7","volume":"23","author":"C Challis","year":"2020","unstructured":"Challis, C. et al. Gut-seeded alpha-synuclein fibrils promote gut dysfunction and brain pathology specifically in aged mice. Nat. Neurosci. 23(3), 327\u2013336 (2020).","journal-title":"Nat. Neurosci."},{"issue":"4","key":"82139_CR10","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/j.neuron.2019.05.035","volume":"103","author":"S Kim","year":"2019","unstructured":"Kim, S. et al. Transneuronal Propagation of pathologic alpha-synuclein from the gut to the Brain models Parkinson\u2019s Disease. Neuron 103(4), 627\u2013641e7 (2019).","journal-title":"Neuron"},{"issue":"4","key":"82139_CR11","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1007\/s00401-019-02040-w","volume":"138","author":"N Van Den Berge","year":"2019","unstructured":"Van Den Berge, N. et al. Evidence for bidirectional and trans-synaptic parasympathetic and sympathetic propagation of alpha-synuclein in rats. Acta Neuropathol. 138(4), 535\u2013550 (2019).","journal-title":"Acta Neuropathol."},{"issue":"5","key":"82139_CR12","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1093\/brain\/awaa096","volume":"143","author":"ML Arotcarena","year":"2020","unstructured":"Arotcarena, M. L. et al. Bidirectional gut-to-brain and brain-to-gut propagation of synucleinopathy in non-human primates. Brain 143(5), 1462\u20131475 (2020).","journal-title":"Brain"},{"issue":"12","key":"82139_CR13","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1016\/S1474-4422(19)30320-5","volume":"18","author":"MA Nalls","year":"2019","unstructured":"Nalls, M. A. et al. Identification of novel risk loci, causal insights, and heritable risk for Parkinson\u2019s disease: a meta-analysis of genome-wide association studies. Lancet Neurol. 18(12), 1091\u20131102 (2019).","journal-title":"Lancet Neurol."},{"issue":"1","key":"82139_CR14","doi-asserted-by":"publisher","first-page":"6958","DOI":"10.1038\/s41467-022-34667-x","volume":"13","author":"ZD Wallen","year":"2022","unstructured":"Wallen, Z. D. et al. Metagenomics of Parkinson\u2019s disease implicates the gut microbiome in multiple disease mechanisms. Nat. Commun. 13(1), 6958 (2022).","journal-title":"Nat. Commun."},{"issue":"5","key":"82139_CR15","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1002\/mds.26942","volume":"32","author":"EM Hill-Burns","year":"2017","unstructured":"Hill-Burns, E. M. et al. Parkinson\u2019s disease and Parkinson\u2019s disease medications have distinct signatures of the gut microbiome. Mov. Disord 32(5), 739\u2013749 (2017).","journal-title":"Mov. Disord"},{"issue":"1","key":"82139_CR16","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/s41531-021-00156-z","volume":"7","author":"S Romano","year":"2021","unstructured":"Romano, S. et al. Meta-analysis of the Parkinson\u2019s disease gut microbiome suggests alterations linked to intestinal inflammation. NPJ Parkinsons Dis. 7(1), 27 (2021).","journal-title":"NPJ Parkinsons Dis."},{"key":"82139_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.parkreldis.2021.11.017","volume":"94","author":"TS Toh","year":"2022","unstructured":"Toh, T. S. et al. Gut microbiome in Parkinson\u2019s disease: new insights from meta-analysis. Parkinsonism Relat. Disord 94, 1\u20139 (2022).","journal-title":"Parkinsonism Relat. Disord"},{"issue":"3","key":"82139_CR18","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1002\/mds.29300","volume":"38","author":"JC Boktor","year":"2023","unstructured":"Boktor, J. C. et al. Integrated Multi-cohort Analysis of the Parkinson\u2019s Disease Gut Metagenome. Mov. Disord 38(3), 399\u2013409 (2023).","journal-title":"Mov. Disord"},{"issue":"1","key":"82139_CR19","doi-asserted-by":"publisher","first-page":"1866974","DOI":"10.1080\/19490976.2020.1866974","volume":"13","author":"Y Bhattarai","year":"2021","unstructured":"Bhattarai, Y. et al. Role of gut microbiota in regulating gastrointestinal dysfunction and motor symptoms in a mouse model of Parkinson\u2019s disease. Gut Microbes 13(1), 1866974 (2021).","journal-title":"Gut Microbes"},{"key":"82139_CR20","doi-asserted-by":"publisher","first-page":"34477","DOI":"10.1038\/srep34477","volume":"6","author":"SG Chen","year":"2016","unstructured":"Chen, S. G. et al. Exposure to the functional bacterial amyloid protein Curli enhances alpha-synuclein aggregation in aged Fischer 344 rats and Caenorhabditis elegans. Sci. Rep. 6, 34477 (2016).","journal-title":"Sci. Rep."},{"issue":"1","key":"82139_CR21","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1038\/s41598-018-19646-x","volume":"8","author":"JG Choi","year":"2018","unstructured":"Choi, J. G. et al. Oral administration of Proteus mirabilis damages dopaminergic neurons and motor functions in mice. Sci. Rep. 8(1), 1275 (2018).","journal-title":"Sci. Rep."},{"issue":"17","key":"82139_CR22","doi-asserted-by":"publisher","first-page":"6915","DOI":"10.18632\/aging.102221","volume":"11","author":"Y Pu","year":"2019","unstructured":"Pu, Y. et al. Antibiotic-induced microbiome depletion protects against MPTP-induced dopaminergic neurotoxicity in the brain. Aging (Albany NY) 11(17), 6915\u20136929 (2019).","journal-title":"Aging (Albany NY)"},{"issue":"6","key":"82139_CR23","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1016\/j.cell.2016.11.018","volume":"167","author":"TR Sampson","year":"2016","unstructured":"Sampson, T. R. et al. Gut microbiota regulate Motor deficits and neuroinflammation in a model of Parkinson\u2019s Disease. Cell 167(6), 1469\u20131480e12 (2016).","journal-title":"Cell"},{"issue":"5","key":"82139_CR24","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1002\/jnr.10231","volume":"68","author":"E Rockenstein","year":"2002","unstructured":"Rockenstein, E. et al. Differential neuropathological alterations in transgenic mice expressing alpha-synuclein from the platelet-derived growth factor and Thy-1 promoters. J. Neurosci. Res. 68(5), 568\u2013578 (2002).","journal-title":"J. Neurosci. Res."},{"issue":"2","key":"82139_CR25","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s13311-012-0104-2","volume":"9","author":"MF Chesselet","year":"2012","unstructured":"Chesselet, M. F. et al. A progressive mouse model of Parkinson\u2019s disease: the Thy1-aSyn (line 61) mice. Neurotherapeutics 9(2), 297\u2013314 (2012).","journal-title":"Neurotherapeutics"},{"issue":"19","key":"82139_CR26","doi-asserted-by":"publisher","first-page":"3047","DOI":"10.1093\/bioinformatics\/btw354","volume":"32","author":"P Ewels","year":"2016","unstructured":"Ewels, P. et al. MultiQC: summarize analysis results for multiple tools and samples in a single report. Bioinformatics 32(19), 3047\u20133048 (2016).","journal-title":"Bioinformatics"},{"key":"82139_CR27","doi-asserted-by":"crossref","unstructured":"Beghini, F. et al. Integrating taxonomic, functional, and strain-level profiling of diverse microbial communities with bioBakery 3 Elife, 10. (2021).","DOI":"10.7554\/eLife.65088"},{"issue":"1","key":"82139_CR28","first-page":"32","volume":"26","author":"MJ Anderson","year":"2001","unstructured":"Anderson, M. J. A new method for non-parametric multivariate analysis of variance. Austral Ecol. 26(1), 32\u201346 (2001).","journal-title":"Austral Ecol."},{"issue":"11","key":"82139_CR29","doi-asserted-by":"publisher","first-page":"e1009442","DOI":"10.1371\/journal.pcbi.1009442","volume":"17","author":"H Mallick","year":"2021","unstructured":"Mallick, H. et al. Multivariable association discovery in population-scale meta-omics studies. PLoS Comput. Biol. 17(11), e1009442 (2021).","journal-title":"PLoS Comput. Biol."},{"issue":"1","key":"82139_CR30","doi-asserted-by":"publisher","first-page":"3514","DOI":"10.1038\/s41467-020-17041-7","volume":"11","author":"H Lin","year":"2020","unstructured":"Lin, H. & Peddada, S. D. Analysis of compositions of microbiomes with bias correction. Nat. Commun. 11(1), 3514 (2020).","journal-title":"Nat. Commun."},{"issue":"7","key":"82139_CR31","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1002\/sim.4780090710","volume":"9","author":"Y Hochberg","year":"1990","unstructured":"Hochberg, Y. & Benjamini, Y. More powerful procedures for multiple significance testing. Stat. Med. 9(7), 811\u2013818 (1990).","journal-title":"Stat. Med."},{"issue":"2","key":"82139_CR32","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.expneurol.2012.06.025","volume":"237","author":"MB Watson","year":"2012","unstructured":"Watson, M. B. et al. Regionally-specific microglial activation in young mice over-expressing human wildtype alpha-synuclein. Exp. Neurol. 237(2), 318\u2013334 (2012).","journal-title":"Exp. Neurol."},{"issue":"8","key":"82139_CR33","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1097\/WNR.0b013e3282ffda5e","volume":"19","author":"L Wang","year":"2008","unstructured":"Wang, L. et al. Abnormal colonic motility in mice overexpressing human wild-type alpha-synuclein. Neuroreport 19(8), 873\u2013876 (2008).","journal-title":"Neuroreport"},{"issue":"9","key":"82139_CR34","doi-asserted-by":"publisher","first-page":"e425","DOI":"10.1111\/j.1365-2982.2012.01974.x","volume":"24","author":"L Wang","year":"2012","unstructured":"Wang, L. et al. Mice overexpressing wild-type human alpha-synuclein display alterations in colonic myenteric ganglia and defecation. Neurogastroenterol Motil. 24(9), e425\u2013e436 (2012).","journal-title":"Neurogastroenterol Motil."},{"key":"82139_CR35","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1038\/ncomms2534","volume":"4","author":"C Kim","year":"2013","unstructured":"Kim, C. et al. Neuron-released oligomeric alpha-synuclein is an endogenous agonist of TLR2 for paracrine activation of microglia. Nat. Commun. 4, 1562 (2013).","journal-title":"Nat. Commun."},{"issue":"5","key":"82139_CR36","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1002\/mds.27326","volume":"33","author":"MC Houser","year":"2018","unstructured":"Houser, M. C. et al. Stool Immune profiles Evince gastrointestinal inflammation in Parkinson\u2019s Disease. Mov. Disord. 33(5), 793\u2013804 (2018).","journal-title":"Mov. Disord"},{"issue":"5","key":"82139_CR37","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.3233\/JPD-223165","volume":"12","author":"N Radisavljevic","year":"2022","unstructured":"Radisavljevic, N. et al. Effects of Gut Microbiota alterations on motor, gastrointestinal, and behavioral phenotype in a mouse model of Parkinson\u2019s Disease. J. Parkinsons Dis. 12(5), 1479\u20131495 (2022).","journal-title":"J. Parkinsons Dis."},{"key":"82139_CR38","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41531-020-0112-6","volume":"6","author":"ZD Wallen","year":"2020","unstructured":"Wallen, Z. D. et al. Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens. NPJ Parkinsons Dis. 6, 11 (2020).","journal-title":"NPJ Parkinsons Dis."},{"key":"82139_CR39","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.bbi.2018.02.005","volume":"70","author":"MF Sun","year":"2018","unstructured":"Sun, M. F. et al. Neuroprotective effects of fecal microbiota transplantation on MPTP-induced Parkinson\u2019s disease mice: gut microbiota, glial reaction and TLR4\/TNF-alpha signaling pathway. Brain Behav. Immun. 70, 48\u201360 (2018).","journal-title":"Brain Behav. Immun."},{"issue":"1","key":"82139_CR40","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s13311-022-01338-0","volume":"20","author":"F Richter","year":"2023","unstructured":"Richter, F. et al. A mouse model to test Novel therapeutics for Parkinson\u2019s Disease: an update on the Thy1-aSyn (line 61) mice. Neurotherapeutics 20(1), 97\u2013116 (2023).","journal-title":"Neurotherapeutics"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-82139-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-82139-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-82139-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T13:22:51Z","timestamp":1738416171000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-82139-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,1]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["82139"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-82139-7","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2024.02.01.578464","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,1]]},"assertion":[{"value":"28 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All research conducted on animals was approved by the Institutional Animal Care and Use Committee of the University of Alabama at Birmingham.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors have read and approved the final manuscript for publication.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"4014"}}